Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 62,323 |
Ending reported balance
After 2023-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-28 · Tax withholding · Disposed 5,438 · Balance 63,662 Row 2 · 2023-03-01 · Sale · Disposed 1,339 · Balance 62,323 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 3, 2023 00:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,339 | $100.70 | $134,837.30 |
DisclosureSEC source: 0001415889-23-003910 · form4-03032023_120319.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,323 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,438 | $99.77 | $542,549.26 |
DisclosureSEC source: 0001415889-23-003910 · form4-03032023_120319.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,662 Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 62,527 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003055 · form4-02232023_120214.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,527 Underlying: Common Shares · 62,527 shares Expires 2033-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,842 on February 17, 2024, 20,842 on February 17, 2025, and 20,843 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003055 · form4-02232023_120214.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,100 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,008 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-22-009508 · form4-09092022_020900.xml · derivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 23,008 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 23,008 | $107.00 | $2,461,856.00 |
DisclosureSEC source: 0001415889-22-009508 · form4-09092022_020900.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,245 Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,008 | $44.40 | $1,021,555.20 |
DisclosureSEC source: 0001415889-22-009508 · form4-09092022_020900.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,008 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-22-009123 · form4-08262022_020840.xml · derivative · entry 4 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,008 Underlying: Common Shares · 23,008 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,890 | $105.24 | $409,383.60 |
DisclosureSEC source: 0001415889-22-009123 · form4-08262022_020840.xml · nonDerivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,245 Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 23,008 | $104.99 | $2,415,704.25 |
DisclosureSEC source: 0001415889-22-009123 · form4-08262022_020840.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,135 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.59 to $105.37, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,008 | $44.40 | $1,021,555.20 |
DisclosureSEC source: 0001415889-22-009123 · form4-08262022_020840.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Since the date of the reporting person's last ownership report, he transferred 3,738 shares and employee stock options to purchase 69,500 shares in the aggregate to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 779 | $118.16 | $92,046.80 |
DisclosureSEC source: 0001415889-22-002196 · form4-03022022_040308.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,873 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,850 | $122.41 | $716,098.50 |
DisclosureSEC source: 0001415889-22-002196 · form4-03022022_040308.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,652 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 72,342 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001740 · form4-02232022_050218.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,342 Underlying: Common Shares · 72,342 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,114 on February 18, 2023, 24,114 on February 18, 2024, and 24,114 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001740 · form4-02232022_050218.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,502 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. F2 · balance_after: Since the date of the reporting person's last ownership report, he transferred 3,754 shares to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,974 | $121.58 | $726,318.92 |
DisclosureSEC source: 0001415889-21-001209 · form4-03022021_040352.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,733 Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 66,658 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000896 · form4-02232021_040228.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,658 Underlying: Common Shares · 66,658 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,219 on February 19, 2022, 22,219 on February 19, 2023, and 22,220 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000896 · form4-02232021_040228.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,707 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. F2 · balance_after: Since the date of the reporting person's last ownership report, he transferred 10,978 shares and employee stock options to purchase shares 178,060 in the aggregate to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,130 | $123.03 | $385,083.90 |
DisclosureSEC source: 0001415889-21-000529 · form4-02032021_040232.xml · nonDerivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,681 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.03 to $123.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 18,750 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-000529 · form4-02032021_040232.xml · derivative · entry 4 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Shares · 18,750 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 18,750 | $122.79 | $2,302,263.75 |
DisclosureSEC source: 0001415889-21-000529 · form4-02032021_040232.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,811 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.75 to $122.8250, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 18,750 | $38.40 | $720,000.00 |
DisclosureSEC source: 0001415889-21-000529 · form4-02032021_040232.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,909 | $79.19 | $467,933.71 |
DisclosureSEC source: 0001179110-20-002923 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,811 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002923 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,720 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 83,818 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002277 · edgar.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,818 Underlying: Common shares · 83,818 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,939 on February 21, 2021, 27,939 on February 21, 2022, and 27,940 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002277 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,284 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 37,500 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-000866 · edgar.xml · derivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common shares · 37,500 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 37,500 | $89.58 | $3,359,411.25 |
DisclosureSEC source: 0001179110-20-000866 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,534 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.52 to $89.65, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 37,500 | $38.40 | $1,440,000.00 |
DisclosureSEC source: 0001179110-20-000866 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 47,226 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010084 · edgar.xml · derivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 47,226 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 47,226 | $85.14 | $4,020,684.68 |
DisclosureSEC source: 0001179110-19-010084 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,532 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.88 to $85.31, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes shares acquires pursuant to a dividend reinvestment feature. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 47,226 | $47.00 | $2,219,622.00 |
DisclosureSEC source: 0001179110-19-010084 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,500 | $79.58 | $437,673.50 |
DisclosureSEC source: 0001179110-19-004149 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,529 Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 113 | $79.57 | $8,991.41 |
DisclosureSEC source: 0001179110-19-004149 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,029 Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,223 | $78.00 | $95,394.00 |
DisclosureSEC source: 0001179110-19-003120 · edgar.xml · nonDerivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,142 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,959 | $77.23 | $305,753.57 |
DisclosureSEC source: 0001179110-19-003120 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,365 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 7,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003120 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,324 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 81,578 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002645 · edgar.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,578 Underlying: Common shares · 81,578 shares Expires 2029-02-21 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,192 on February 22, 2020, 27,193 on February 22, 2021, and 27,193 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002645 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,036 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,430 | $58.98 | $84,344.26 |
DisclosureSEC source: 0001179110-18-003312 · edgar.xml · nonDerivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,466 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,786 | $60.55 | $168,692.30 |
DisclosureSEC source: 0001179110-18-003312 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,896 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,520 | $60.55 | $576,436.00 |
DisclosureSEC source: 0001179110-18-003312 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,682 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 61,192 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002539 · edgar.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,192 Underlying: Common shares · 61,192 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,398 on 02/16/2019, 20,397 on 02/16/2020, and 20,397 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 22, 2018 00:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002539 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,162 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,200 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-006289 · edgar.xml · derivative · entry 9 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 3,200 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $43.97 | $26,383.80 |
DisclosureSEC source: 0001179110-17-006289 · edgar.xml · nonDerivative · entry 8 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,024 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $43.97 | $17,588.40 |
DisclosureSEC source: 0001179110-17-006289 · edgar.xml · nonDerivative · entry 7 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,624 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $43.95 | $101,078.10 |
DisclosureSEC source: 0001179110-17-006289 · edgar.xml · nonDerivative · entry 6 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,024 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $43.95 | $21,972.50 |
DisclosureSEC source: 0001179110-17-006289 · edgar.xml · nonDerivative · entry 5 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,324 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $43.94 | $4,394.30 |
DisclosureSEC source: 0001179110-17-006289 · edgar.xml · nonDerivative · entry 4 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,824 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.